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o investigate the effect of Bcl-2 on Ca
 
2
 
 
 
 signaling
in T cells, we continuously monitored Ca
 
2
 
 
 
 concen-
tration in Bcl-2–positive and –negative clones of the
WEHI7.2 T cell line after T cell receptor (TCR) activation
by anti-CD3 antibody. In Bcl-2–negative cells, high con-
centrations of anti-CD3 antibody induced a transient
Ca
 
2
 
 
 
 elevation, triggering apoptosis. In contrast, low
concentrations of anti-CD3 antibody induced Ca
 
2
 
 
 
 oscil-
lations, activating the nuclear factor of activated T cells
(NFAT), a prosurvival transcription factor. Bcl-2 blocked
the transient Ca
 
2
 
 
 
 elevation induced by high anti-CD3,
T
 
thereby inhibiting apoptosis, but did not inhibit Ca
 
2
 
 
 
 os-
cillations and NFAT activation induced by low anti-CD3.
Reduction in the level of all three inositol 1,4,5-trisphos-
phate (InsP
 
3
 
) receptor subtypes by small interfering RNA
inhibited the Ca
 
2
 
 
 
 elevation induced by high but not low
anti-CD3, suggesting that Ca
 
2
 
 
 
 responses to high and
low anti-CD3 may have different requirements for the
InsP
 
3
 
 receptor. Therefore, Bcl-2 selectively inhibits pro-
apoptotic Ca
 
2
 
 
 
 elevation induced by strong TCR activa-
tion without hindering prosurvival Ca
 
2
 
 
 
 signals induced
by weak TCR activation.
 
Introduction
 
Ca
 
2
 
 
 
 is a versatile second messenger that mediates a wide
range of cellular processes, including cell division and apoptosis
(Berridge et al., 2003). Under physiological conditions, cyto-
plasmic Ca
 
2
 
 
 
 is maintained at a low level, and it is the eleva-
tion of cytoplasmic Ca
 
2
 
 
 
 that generates Ca
 
2
 
 
 
 signals. Elevated
Ca
 
2
 
 
 
 transmits information by activating Ca
 
2
 
 
 
-sensitive effec-
tors, including phosphatases and kinases. The Ca
 
2
 
 
 
 elevation
involved in signal transduction is often in the form of repetitive
Ca
 
2
 
 
 
 spikes or oscillations (Berridge, 1997b). The information-
processing capability of Ca
 
2
 
 
 
 signaling is enhanced by modula-
tion of the frequency, amplitude, and spatial properties of Ca
 
2
 
 
 
elevations. This in part explains how a simple messenger such
as Ca
 
2
 
 
 
 can regulate diverse cellular processes.
In T cells, Ca
 
2
 
 
 
 signals mediate a variety of responses to T
cell receptor (TCR) activation, including cell proliferation and
apoptosis (Winslow et al., 2003; for reviews see Berridge, 1997a;
Lewis, 2001, 2003; Randriamampita and Trautmann, 2004).
As in all nonexcitable cells, the T cell Ca
 
2
 
 
 
 response begins with
the release of Ca
 
2
 
 
 
 from the ER through inositol 1,4,5-trisphos-
phate (InsP
 
3
 
)–dependent Ca
 
2
 
 
 
 channels (InsP
 
3
 
 receptors). The
resulting cytoplasmic Ca
 
2
 
 
 
 elevation is amplified by Ca
 
2
 
 
 
 entry
through Ca
 
2
 
 
 
-release–activated Ca
 
2
 
 
 
 channels on the plasma
membrane, producing either a transient Ca
 
2
 
 
 
 elevation or Ca
 
2
 
 
 
oscillations (Donnadieu et al., 1992a,b; Hess et al., 1993; for
review see Lewis, 2001). The Ca
 
2
 
 
 
 signal is then transduced
through Ca
 
2
 
 
 
/calmodulin–mediated activation of the protein
phosphatase calcineurin, which dephosphorylates and thereby
activates the nuclear factor of activated T cells (NFAT; for re-
view see Lewis, 2003; Winslow et al., 2003). NFAT is a tran-
scription factor that activates the interleukin-2 promoter, in-
creasing cell proliferation. Activation of calcineurin, and
hence NFAT, is sustained more efficiently by Ca
 
2
 
 
 
 oscillations
than by a transient elevation of Ca
 
2
 
 
 
, whereas other Ca
 
2
 
 
 
 re-
sponses (e.g., nuclear factor kB and c-Jun NH
 
2
 
-terminal kinase
activation) are preferentially activated by transient Ca
 
2
 
 
 
 elevation
(Dolmetsch et al., 1997, 1998). The importance of Ca
 
2
 
 
 
 oscilla-
tions in T cell signaling is increasingly recognized, including
evidence that Ca
 
2
 
 
 
 oscillations regulate thymocyte motility
during positive selection in the thymus (Bhakta et al., 2005).
We recently reported that the antiapoptotic protein Bcl-2
(Cory and Adams, 2002) interacts with InsP
 
3
 
 receptors on the
ER and inhibits InsP
 
3
 
-mediated Ca
 
2
 
 
 
 efflux (Chen et al., 2004).
As a consequence, Bcl-2 dampens the cytoplasmic Ca
 
2
 
 
 
 eleva-
tion induced by an antibody to the CD3 component of the TCR
complex. These findings are intriguing in view of the known
role of Ca
 
2
 
 
 
 in signaling apoptosis (for reviews see Hajnoczky
et al., 2003; Orrenius et al., 2003; Hanson et al., 2004), but an
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inhibitory effect of Bcl-2 on InsP
 
3
 
-mediated Ca
 
2
 
 
 
 elevation
would seem incompatible with the wide range of physiological
processes governed by InsP
 
3
 
-mediated Ca
 
2
 
 
 
 signals. Would not
Bcl-2 interfere with Ca
 
2
 
 
 
 signals that regulate physiological
processes required for cell function and survival?
A possible clue to this dilemma was provided by earlier
work indicating that Ca
 
2
 
 
 
 responses after TCR activation vary
according to the strength of TCR activation (Donnadieu et al.,
1992a). Typically, strong signals induced by a high concentra-
tion of anti-CD3 antibody trigger a single transient elevation of
cytoplasmic Ca
 
2
 
 
 
, whereas weaker signals induced by a low
concentration of anti-CD3 induce Ca
 
2
 
 
 
 oscillations (Donnadieu
et al., 1992a). Our previous experiments demonstrating an in-
hibitory effect of Bcl-2 on anti-CD3–induced Ca
 
2
 
 
 
 elevation
used a high concentration of anti-CD3 antibody that induced a
transient Ca
 
2
 
 
 
 elevation rather than Ca
 
2
 
 
 
 oscillations. There-
fore, in the present work, we investigated the effect of Bcl-2 on
Ca
 
2
 
 
 
 signals induced over a broad range of anti-CD3 concen-
trations. This led to the discovery that Bcl-2 differentially regu-
lates Ca
 
2
 
 
 
 signals according to the strength of TCR activation.
Thus, Bcl-2 inhibited the transient Ca
 
2
 
 
 
 elevation induced by a
high concentration of anti-CD3 antibody, without interfering
with Ca
 
2
 
 
 
 oscillations induced by a low concentration of anti-
CD3 antibody. Accordingly, Bcl-2 inhibited Ca
 
2
 
 
 
-mediated
apoptosis after strong TCR activation but did not inhibit NFAT
activation after weak TCR activation. Therefore, by selectively
regulating Ca
 
2
 
 
 
 signals according to the strength of TCR acti-
vation, Bcl-2 discriminates between proapoptotic and prosur-
vival Ca
 
2
 
 
 
 signals.
 
Results
 
Bcl-2 inhibits Ca
 
2
 
 
 
 elevation induced by 
high but not low anti-CD3 antibody
 
The WEHI7.2 T cell line corresponds to an immature double-
positive stage of T cell differentiation, as WEHI7.2 cells express
both CD4 and -8 antigens and are sensitive to glucocorticosteroid-
induced apoptosis. Consistent with this stage of development,
Bcl-2 is virtually undetectable in WEHI7.2 cells. In earlier
work, Bcl-2–positive and –negative clones were derived by
stably transfecting WEHI7.2 cells with an expression vector
encoding full-length human Bcl-2 or an empty vector, respec-
tively. The full characterization of the clones used in this work
has been reported previously (Chen et al., 2004). All findings
reported here are based on comparison of three Bcl-2–positive
and three Bcl-2–negative clones. Findings were consistent
Figure 1. Ca
2  responses to high and low anti-CD3 differ
and are differentially regulated by Bcl-2. (A) Cytoplasmic
Ca
2  was continuously monitored by digital imaging in
Bcl-2–negative WEHI7.2 cells (clone N2) before and after
addition of anti-CD3 antibody (experiments 110504–
111904). Bars represent the percentage of cells on a
single coverslip ( 50 cells per coverslip) that developed
either a transient elevation of Ca
2  or sustained oscilla-
tions at each anti-CD3 concentration. In control experi-
ments, no Ca
2  elevation was detected in the absence of
anti-CD3 treatment (not depicted). (B) Cytoplasmic Ca
2 
was monitored continuously by digital imaging in Bcl-2–
negative and –positive cells after addition of anti-CD3 an-
tibody at the concentrations shown. Bars represent the
percentage of cells developing either a transient Ca
2  el-
evation (left) or Ca
2  oscillations (right). Error bars repre-
sent the mean   SEM of multiple experiments (20  g/ml:
6 experiments, mean 40 cells per experiment; 2  g/ml:
24 experiments in Bcl-2–negative cells, mean 25 cells per
experiment, and 22 experiments in Bcl-2–positive cells,
mean 33 cells per experiment; 0.75  g/ml: 7 experi-
ments in Bcl-2–negative cells, mean 53 cells per experi-
ment, and 6 experiments in Bcl-2–positive cells, mean 39
cells per experiment; 0.33  g/ml: 4 experiments for Bcl-
2–negative cells, mean 60 cells per experiment, and 4
experiments for Bcl-2–positive cells, mean 54 cells per ex-
periment). (C) The peak amplitude of each Ca
2  eleva-
tion induced by the different concentrations of anti-CD3
antibody is summarized based on the same experiments
as in B. (D) The width of transient elevations induced by
20  g/ml anti-CD3 and both transient elevations and
oscillatory spikes induced by 2  g/ml anti-CD3 were re-
corded. The width was measured at one third of the peak
height. Data are from experiments 110804N2 (29 tran-
sient elevations) and 110504B17 (19 transient eleva-
tions) at 20  g/ml and experiments 110804N2 (119
elevations) and 110804B17 (66 elevations) at 2  g/ml
anti-CD3. Data from three Bcl-2–negative clones (N2, -10,
and -11) and three Bcl-2–positive clones (B6, -9, and -17)
were in agreement and therefore were combined in B–D.
Error bars represent mean   SEM. Asterisks designate a
statistically significant difference (P   0.01). 
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among the different clones; therefore, data from individual
clones have been pooled, unless otherwise noted.
Throughout this paper, cytoplasmic Ca
 
2
 
 
 
 was measured
at a single-cell level by digital imaging. An initial series of
Ca
 
2
 
 
 
 measurements was performed to determine the dose–
response relationship between anti-CD3 concentration and
cytoplasmic Ca
 
2
 
 
 
 response patterns in a Bcl-2–negative clone
(Fig. 1 A). In this experiment, a transient elevation of Ca
2  was
defined as only one or two Ca
2  elevations reaching at least
twice the basal level of Ca
2 , whereas sustained Ca
2  oscilla-
tions were defined as three or more Ca
2  spikes at least twice
the basal level of Ca
2  and separated by at least a 30-s interval.
The percentage of cells responding with a transient Ca
2  eleva-
tion was maximal at 20  g/ml anti-CD3 antibody and declined
progressively with increasing antibody dilution (Fig. 1 A).
Conversely, the percentage of cells developing Ca
2  oscillations
increased progressively as anti-CD3 antibody concentration was
reduced. Thus, there is a reciprocal dose–response relationship
for transient elevations of Ca
2  versus Ca
2  oscillations after
TCR activation. Based on these initial findings, subsequent stud-
ies used 20  g/ml as representative of a high concentration of
anti-CD3 antibody and 2, 0.75, and 0.33  g/ml as representative
of low concentrations of anti-CD3 antibody.
Representative Ca
2  traces comparing Bcl-2–negative
and –positive cells at a high anti-CD3 concentration (20  g/ml)
are shown in Fig. 2. Bcl-2–negative cells responded to high
anti-CD3 with an almost synchronous elevation of cytoplasmic
Ca
2  as shown in Fig. 2 A, where multiple single-cell Ca
2 
traces collected in a single experiment (i.e., a single micro-
scope coverslip) are plotted together. In contrast, only a small
proportion of Bcl-2–positive cells responded with a detectable
Ca
2  elevation (Fig. 2 E). The inhibitory effect of Bcl-2 on
anti-CD3–induced Ca
2  elevation in these experiments is also
illustrated by averaging the Ca
2  response of multiple cells
(Fig. 2, B and F). Characteristics of Ca
2  responses at a single-
cell level are illustrated by the Ca
2  traces in Fig. 2 (C, D, G,
and H). Though the number of responding cells and the ampli-
tude of Ca
2  elevations differed markedly between Bcl-2–neg-
ative and –positive cells, the shape of the Ca
2  elevation was
similar. In a small percentage of cells, secondary Ca
2  eleva-
tions were observed (e.g., Fig. 2 H), but as noted in Fig. 1 B,
sustained oscillations were infrequent.
Representative Ca
2  traces comparing Bcl-2–negative
and –positive cells at lower concentrations of anti-CD3 anti-
body (2, 0.75, and 0.33  g/ml) are shown in Fig. 3. In contrast
to the broad elevation of Ca
2  triggered at 20  g/ml anti-CD3,
the Ca
2  responses at low concentrations of anti-CD3 antibody
were typically in the form of narrow spikes. Also, in contrast to
the inhibitory effect of Bcl-2 on Ca
2  responses at high anti-
CD3, Bcl-2 did not inhibit the Ca
2  spikes evoked by low con-
centrations of anti-CD3. This is illustrated by the representative
traces shown in Fig. 3. In Fig. 3, B–D and F–H show repetitive
Ca
2  spikes, or oscillations, detected in both Bcl-2–negative
and –positive cells over the range of anti-CD3 concentrations
tested, whereas A and E show cells where only one or two Ca
2 
spikes were detected. Note that the Ca
2  oscillations induced
by low anti-CD3 were irregular in terms of both amplitude and
frequency. This is characteristic of Ca
2  oscillations in T cells,
as reported previously, and is in contrast to the more uniform
pattern of Ca
2  oscillations observed in nonlymphoid cells
(for reviews see Lewis, 2001; Randriamampita and Traut-
mann, 2004). Also, spontaneous Ca
2  oscillations were not de-
tected in control experiments where anti-CD3 was not added to
cells.
The responses of cells to either high (20  g/ml) or low
(2, 0.75, or 0.33  g/ml) anti-CD3 in a large number of experi-
ments are summarized in Fig. 1 (B and C). These data indicate
that oscillations are much more frequent at the low than at the
high concentration of anti-CD3 (Fig. 1 B). Moreover, these data
Figure 2. Bcl-2 inhibits the transient Ca
2  elevation induced by high anti-
CD3 antibody. Cytoplasmic Ca
2  was continuously monitored by digital
imaging in Bcl-2–negative (clone N10) and –positive (clone B6) cells be-
fore  and after addition of 20  g/ml anti-CD3 antibody (experiments
022305N10 and 022305B6). Antibody was added during the first 2 min
of the trace. (A–D) Bcl-2–negative cells; (E–H) Bcl-2–positive cells. (A) Com-
bined single-cell Ca
2  traces from a total of 51 cells on a single coverslip.
(E) Combined single-cell Ca
2  traces from a total of 53 cells on a single
coverslip. (B and F) Mean Ca
2  trace for the cells in A and E, respectively.
(C, D, G, and H) Single-cell Ca
2  traces, illustrating the range of amplitudes
of the transient Ca
2  elevations obtained at this high anti-CD3 concentration
in Bcl-2–negative cells (C and D) and the reduced amplitude of Ca
2  tran-
sients in Bcl-2–positive cells (G and H). Single-cell traces were from experi-
ments 022305N10 (cells AB and AM) and 022305B6 (cells K and J).JCB • VOLUME 172 • NUMBER 1 • 2006 130
confirm that Bcl-2 markedly inhibits Ca
2  responses to strong
TCR activation (20  g/ml anti-CD3 antibody), based on a sig-
nificant (P   0.01) reduction in both the percentage of cells that
respond (Fig. 1 B) and the amplitude of Ca
2  elevations in those
cells that do respond (Fig. 1 C). In contrast, Bcl-2 did not inhibit
Ca
2  responses to weak TCR activation (2, 0.75, or 0.33  g/ml
anti-CD3 antibody), based on the percentage of cells that re-
spond (Fig. 1 B) and the mean amplitude of Ca
2  spikes (Fig.
1 C). Interestingly, at low anti-CD3 in Bcl-2–positive cells,
there was a small but insignificant (P   0.10) reduction in the
percentage of cells developing a transient Ca
2  elevation (i.e.,
one or two Ca
2  spikes; Fig. 1 B, left) and a small but insignifi-
cant (P   0.10) increase in the percentage of cells developing
sustained Ca
2  oscillations (i.e., three or more Ca
2  spikes; Fig.
1 B, right). Moreover, the mean amplitude of Ca
2  spikes at the
lowest anti-CD3 concentration (.33  g/ml) was higher in Bcl-2–
positive than in Bcl-2–negative cells (Fig. 1 C), although this
difference was not statistically significant (P   0.10).
As noted in Fig. 1 D, a major difference between the Ca
2 
elevations induced at high versus low anti-CD3 antibody con-
centrations was in the duration (i.e., width) of the individual
Ca
2  peaks. This is illustrated by the representative Ca
2  traces
in Figs. 2 and 3 and is also documented quantitatively in Fig. 1 D.
The mean peak width was 4 min at 20  g/ml anti-CD3 anti-
body but  1 min at 2  g/ml anti-CD3 antibody. Moreover,
Bcl-2 did not alter the width of individual Ca
2  elevations (either
transient induced by high anti-CD3 or transient and oscillatory
at low anti-CD3; Fig. 1 D).
Detailed comparisons of Ca
2  oscillations induced by
low concentrations of anti-CD3 antibody in Bcl-2–negative
and –positive cells are summarized in Fig. 4. To quantitatively
compare the oscillatory frequency in Bcl-2–positive and –negative
cells, Ca
2  traces from numerous experiments were separated
into successive 5-min time periods and the number of Ca
2 
spikes during each period was logged, a method that has been
described previously (Bird and Putney, 2005; Fig. 4, A and B).
Figure 3. Bcl-2 does not inhibit Ca
2  oscilla-
tions induced by low anti-CD3 antibody. Cyto-
plasmic Ca
2  was continuously monitored by
digital imaging in Bcl-2–negative (A–D) and
–positive (E–H) cells before and after addition
of 2, 0.75, or 0.33  g/ml anti-CD3 antibody.
Antibody was added during the first 2 min of
the trace. A and E illustrate cells with only two
Ca
2  spikes, whereas B–D and F–H illustrate
sustained Ca
2  oscillations (three or more
spikes). Links to original data files are as follows:
A, 090104N11, cell AA; B, 090104N11,
cell AI; C, 080505, cell BG; D, 082305, cell
G; E, 070104, cell H; F, 070104, cell K; G,
080505, cell G; H, 082405, cell AE.CALCIUM REGULATION BY BCL-2 • ZHONG ET AL. 131
Overall, the frequency of Ca
2  oscillations induced by 2  g/ml
anti-CD3 antibody appeared higher in Bcl-2–positive than in
Bcl-2–negative cells, although differences reached statistical
significance only during the 15-min time interval (P   0.01)
and borderline significance during the 10-min time interval
(P   0.057; Fig. 4 A). The frequency of oscillations also ap-
peared to be higher in Bcl-2–positive cells at 0.75  g/ml anti-
CD3 antibody, but differences were not statistically significant
at any of the time intervals (Fig. 4 B). To analyze oscillatory
frequency by a different method, the time interval between
Ca
2  spikes was measured in multiple Ca
2  traces at 2  g/ml
anti-CD3 antibody and, based on these data, mean and mode
frequencies were calculated. The mean frequency of Ca
2  os-
cillations in Bcl-2–negative cells was 5.2   0.6 mHz, whereas
the mode frequency was 7.3   0.55 mHz. Mean frequency was
lower than mode frequency because of the presence of low-fre-
quency spiking detected in a small proportion of the Ca
2 
traces. The mean frequency was not significantly different in
Bcl-2–negative and –positive cells (Fig. 4 C), but the mode fre-
quency was significantly higher in Bcl-2–positive cells (Fig.
4 D). Thus, consistent with the analysis in Fig. 4 A, this analysis
suggests an increased frequency of Ca
2  oscillations in Bcl-2–
positive compared to Bcl-2–negative cells. The total duration
of Ca
2  oscillatory runs (i.e., time duration from initial to final
Ca
2  spikes) appeared longer in Bcl-2–positive than in Bcl-2–
negative cells, although this difference was of borderline sig-
nificance (P   0.05; Fig. 4 E). WEHI7.2 cells adhered loosely
to coverslips, limiting the rate at which anti-CD3 antibody
could be perfused onto cells. Therefore, to estimate latency period,
the initial Ca
2  response to 2  g/ml anti-CD3 antibody was re-
corded in cell suspensions fluorometrically (Fig. 4 F). Based on
these data, the latency period was on the order of 2 min and was
the same in Bcl-2–negative and –positive cells. Although the pre-
ceding analyses suggest that Bcl-2 may slightly increase the fre-
quency and duration of Ca
2  oscillations, the major conclusion
from these data is that Bcl-2 does not inhibit Ca
2  oscillations in-
duced by low concentrations of anti-CD3 antibody. Consistent
with this finding, Bcl-2 did not inhibit NFAT activation (Fig. 4 G).
Bcl-2 inhibits anti-CD3–induced 
apoptosis by inhibiting anti-CD3–induced 
Ca
2  elevation
The mean amplitudes of Ca
2  elevations induced by high and low
concentrations of anti-CD3 antibody were compared in Fig. 1 C.
Although the mean peak amplitude of the Ca
2  elevation induced
by 20  g/ml anti-CD3 was similar to the mean peak amplitude of
Ca
2  spikes induced by 2  g/ml anti-CD3, the net effect of am-
plitude and width of Ca
2  peak is a much more substantial Ca
2 
elevation after high anti-CD3 than after low anti-CD3. Further-
more, analysis of the peak Ca
2  elevation induced by 20  g/ml
anti-CD3 on an individual cell basis illustrates a broad range of
Ca
2  elevations detected in Bcl-2–negative cells (Fig. 5). 27% of
the Ca
2  spikes in Bcl-2–negative cells were  200 nM, an arbi-
trarily chosen threshold level, whereas only 7% of Ca
2  spikes in
Bcl-2–positive cells were higher than this level after treatment
with 20  g/ml anti-CD3 antibody. Therefore, Bcl-2 not only re-
duces the percentage of cells that elevate Ca
2  in response to high
anti-CD3 (Fig. 1 B) but also dampens Ca
2  elevations in the cells
Figure 4. Comparison of Ca
2  oscillations and NFAT
activation in Bcl-2–negative and –positive cells. (A) Cyto-
plasmic Ca
2  was continuously monitored by digital im-
aging in Bcl-2–negative and –positive cells before and
after addition of 2  g/ml anti-CD3 antibody. Ca
2  traces
were divided into successive 5-min intervals, and the
number of Ca
2  spikes per cell in each 5-min interval was
recorded as a measure of oscillatory frequency. The
analysis was performed on 25 coverslips of Bcl-2–nega-
tive cells and 33 coverslips of Bcl-2–positive cells. The fre-
quency of Ca
2  spike activity appeared higher in Bcl-2–
positive cells at all but the 40-min time period, but the dif-
ference between Bcl-2–negative and –positive cells was
significant only during the 15-min time period (*, P  
0.01) and borderline significant during the 10-min time
period (**, P   0.057). (B) The same method of analysis
was performed on Ca
2  traces at 0.75  g/ml anti-CD3
antibody, although fewer experiments were performed at
this antibody concentration (six coverslips of Bcl-2–negative
cells and five coverslips of Bcl-2–positive cells). None of
the apparent differences between oscillatory frequency in
Bcl-2–negative and –positive cells were statistically signif-
icant (P   0.10). (C) The time period between the peaks
of individual Ca
2  spikes induced by 2  g/ml anti-CD3
antibody was measured and used to calculate the mean
frequency of Ca
2  oscillations. The difference between
Bcl-2–negative and –positive cells was not significant
(P   0.10). (D) The mode frequency of Ca
2  oscillations induced by 2  g/ml anti-CD3 was calculated from the data in C. The mode frequency of oscillations
in Bcl-2–positive cells was higher than that in Bcl-2–negative cells (*, P   0.01). (E) The duration of oscillations induced by 2  g/ml anti-CD3 antibody
was measured as the time between the initial and the final Ca
2  elevations in an oscillatory run. The apparent difference between the duration of oscilla-
tions in Bcl-2–negative and –positive cells was not significant (P   0.10). Error bars represent mean   SEM. In F and G, suspensions of Bcl-2–negative
and –positive cells were treated with 2  g/ml anti-CD3 antibody. (F) The anti-CD3–induced elevation of cytoplasmic Ca
2  was recorded fluorometrically
in fura-2–AM–loaded cells (black line, Bcl-2–negative cells; gray line, Bcl-2–positive cells). (G) Immunoblot documenting NFAT activation by 2  g/ml anti-
CD3 antibody, representative of three separate experiments. The top band depicts phosphorylated (inactive) NFAT, whereas the bottom band shows the
dephosphorylated (activated) form of NFAT.JCB • VOLUME 172 • NUMBER 1 • 2006 132
that do respond by preventing very high peak Ca
2  elevations.
In contrast to the wide distribution of Ca
2  elevations observed at
20  g/ml anti-CD3 antibody in Bcl-2–negative cells, only 6 and
1% of Ca
2  spikes were  200 nM at 2 and 0.75  g/ml anti-CD3
antibody in Bcl-2–negative cells (Fig. 5). Even fewer cells ele-
vated their Ca
2  to  200 nM at these low concentrations of anti-
CD3 antibody in Bcl-2–positive cells (Fig. 5 C). Thus, although
Bcl-2 did not reduce the percentage of cells that responded to low
concentrations of anti-CD3 antibody by developing sustained
Ca
2  oscillations (Fig. 1 B) and did not reduce the mean ampli-
tude of these Ca
2  elevations (Fig. 1 C), it does appear to have set
a threshold level above which the Ca
2  does not elevate even in
response to weak TCR activation.
To investigate the contribution of high Ca
2  elevations to
anti-CD3–induced apoptosis, cells were treated with 20  g/ml
anti-CD3 antibody and sorted by flow cytometry into two differ-
ent populations based on relative levels of cytoplasmic Ca
2 
(Fig. 6 A). The cells were then placed in culture, and the percent-
age of apoptotic cells was measured 24 h later. A significantly
higher percentage of cells in the high Ca
2  population underwent
apoptosis, compared to cells in the low Ca
2  population (Fig.
6 B). Conversely, reducing extracellular Ca
2  concentration, a
condition that partially prevents Ca
2  elevation after treatment
with high anti-CD3 (Fig. 7 A), inhibited apoptosis (Fig. 7 B).
Thus, the induction of apoptosis in Bcl-2–negative cells is Ca
2 
dependent, and the percentage of cells undergoing apoptosis is
proportional to the peak amplitude of Ca
2  elevation after treat-
ment with a high concentration of anti-CD3 antibody. Consistent
with these findings, Bcl-2 inhibited apoptosis induction by high
anti-CD3 (Fig. 7, C and D), in accordance with the dampening
effect of Bcl-2 on anti-CD3–induced Ca
2  elevation described in
preceding experiments (Fig. 5). Treatment with low anti-CD3
did not induce apoptosis (Fig. 7 C), consistent with the evidence
that high Ca
2  elevation ( 200 nM) was much less common
after treatment with low anti-CD3 than it was after treatment
with high anti-CD3 (Fig. 5). Interestingly, the percentage of
apoptotic cells was lower after treatment with low anti-CD3
antibody than it was in untreated cells (Fig. 7 C). This suggests
that treatment with low anti-CD3 may have a prosurvival action,
in contrast to the proapoptotic action of high anti-CD3.
Figure 5. Bcl-2 dampens Ca
2  elevations
induced by anti-CD3 antibody. Peak Ca
2  ele-
vations induced by 20 (left), 2 (middle), and
0.75 (right)  g/ml anti-CD3 in Bcl-2–negative
and –positive cells are represented by dots,
where each dot represents either an individual
transient elevation or an individual oscillatory
spike, arranged at random on the horizontal
axis. The percentage of Ca
2  elevations over
an arbitrary threshold of 200 nM is shown.
Ca
2  elevations to  40 nM were not re-
corded. Data are from multiple experiments
(150 elevations for Bcl-2–negative cells at 20
 g/ml; 58 transient elevations for Bcl-2–posi-
tive cells at 20  g/ml; 758 spikes for Bcl-2–
negative cells at 2  g/ml; 1,430 spikes for
Bcl-2–positive cells at 2  g/ml; 559 spikes for
Bcl-2–negative cells at 0.75  g/ml; 692
spikes for Bcl-2–positive cells at 0.75  g/ml).
Figure 6. High levels of Ca
2  elevation after anti-CD3 treatment are
associated with apoptosis induction. (A) Bcl-2–negative cells were loaded
with the fluorescent Ca
2  indicator calcium green and fluorescence (calcium
green lin, vertical axis) was monitored continuously by flow cytometry be-
fore and after adding anti-CD3 antibody (20  g/ml). Cells were sorted
into two populations corresponding to high and low levels of Ca
2  eleva-
tion. The high Ca
2  group represents 10.7% of the cells sorted, and the
low Ca
2  group represents 72.8% of the cells sorted. The color gradient
represents cellular population density, with yellow representing the area of
highest density and blue representing the area of lowest density. (B) After
24 h in culture, sorted cells were stained with Hoechst 33342 and the
percentage of cells displaying typical apoptotic nuclear morphology was
determined by epifluorescence microscopy. Error bars represent mean  
SEM of two separate experiments.CALCIUM REGULATION BY BCL-2 • ZHONG ET AL. 133
Effect of InsP3 receptor knockdown on 
Ca
2  responses to strong and weak 
TCR activation
To address the question of how Bcl-2 differentially regulates
Ca
2  signals induced by high versus low concentrations of anti-
CD3 antibody, we used small interfering RNA (siRNA) to re-
duce levels of all three InsP3 receptor subtypes in WEHI7.2
cells (Fig. 8). The siRNA olignucleotide pools were introduced
into cells by electroporation with a transfection efficiency of 78  
2% (mean   SEM). The siRNA-mediated reduction in InsP3
receptor levels was documented by Western blotting (Fig. 8 A).
Substantial reduction in all three InsP3 receptor subtypes was
reproducibly achieved (Fig. 8 B). This reduction in InsP3 recep-
tors significantly inhibited the Ca
2  elevation induced by 20
 g/ml anti-CD3 antibody (Fig. 8, C and D). But the siRNA-
mediated reduction in InsP3 receptor levels did not inhibit Ca
2 
responses to 2  g/ml anti-CD3 antibody. This is documented
by representative Ca
2  traces (Fig. 8, E and F), by analysis of
the percentage of responding cells (Fig. 8 G), and by amplitude
analysis (Fig. 8 H). Thus, consistent with the inhibitory effect
of Bcl-2 on Ca
2  responses to strong but not to weak TCR ac-
tivation, the former appears to be more dependent on InsP3
receptor expression levels than the latter.
Discussion
The principal finding in this study is that Bcl-2 differentially
regulates Ca
2  signaling in T cells according to the strength
of TCR activation. Bcl-2 was found to inhibit the cytoplasmic
Ca
2  elevation induced by a high concentration of anti-CD3
antibody but did not inhibit Ca
2  elevation induced by low
concentrations of anti-CD3 antibody. This finding evolved as
a natural extension of our earlier investigation into the effect
of Bcl-2 on InsP3 receptor–mediated Ca
2  release from the
ER (Chen et al., 2004). Those studies initially used fluoro-
metric measurements of Ca
2  elevation in response to a rela-
tively high concentration of anti-CD3 antibody. It was this
Ca
2  elevation that we found to be inhibited by Bcl-2. Although
digital imaging was eventually used in addition to fluorome-
try in these earlier studies, a high concentration of anti-CD3
antibody was adhered to throughout. Thus, only the effect of
Bcl-2 on the transient Ca
2  elevation induced by a relatively
high concentration of anti-CD3 antibody was investigated.
The present study was undertaken based on the prediction
that Ca
2  oscillations would be detected if a lower concentra-
tion of anti-CD3 antibody were used. This prediction was
based on evidence that high concentrations of cell surface re-
ceptor agonists generally induce transient elevations of Ca
2 ,
whereas low concentrations of agonist are more likely to in-
duce sustained oscillations (Berridge, 1990). Consistent with
this paradigm, it was previously reported that strong TCR ac-
tivation induces primarily a transient Ca
2  elevation, whereas
weaker TCR activation induces primarily repetitive Ca
2 
spikes, or oscillations (Donnadieu et al., 1992a).
As anticipated, the Ca
2  response pattern in WEHI7.2
cells underwent a transition from transient Ca
2  elevation to
sustained oscillations as anti-CD3 antibody concentration was
decreased (Fig. 1 A). The Ca
2  oscillations induced by anti-
CD3 antibody were irregular in their amplitude and frequency
(Fig. 3). This is characteristic of Ca
2  oscillations in T cells,
Figure 7. Bcl-2 inhibits Ca
2 -dependent apoptosis induced
by high anti-CD3. (A) Low extracellular Ca
2  inhibits
anti-CD3–induced Ca
2  elevation. Cytoplasmic Ca
2 
was measured by digital imaging in Bcl-2–negative cells
after addition of 20  g/ml anti-CD3 antibody. Antibody
was added during the first 2 min of the trace. The black
line depicts the mean Ca
2  trace corresponding to 63
cells, with measurements performed in 1.3 mM of extra-
cellular Ca
2  buffer, and the gray line depicts the mean
Ca
2  trace corresponding to 60 cells, with measure-
ments performed in nominally Ca
2 -free buffer. (B) Low
extracellular Ca
2  inhibits anti-CD3–induced apoptosis.
Apoptosis was quantified according to nuclear morpho-
logical changes as in Fig. 6, 24 h after adding 20  g/ml
anti-CD3 to Bcl-2–negative cells suspended in regular
DME ( ), which contains 1.3 mM of extracellular Ca
2 ,
or nominally Ca
2 -free DME ( ). Anti-IgG antibody was
added 30 min after anti-CD3 antibody. Error bars repre-
sent mean   SEM in three experiments. The asterisk de-
notes the significant (P   0.01) inhibitory effect of low
extracellular Ca
2  on apoptosis induction. (C) In Bcl-2–
negative cells, apoptosis is induced by 20  g/ml anti-
CD3 antibody but not by 2  g/ml anti-CD3 antibody.
Bcl-2 inhibits apoptosis induction by anti-CD3 antibody.
The percentage of apoptotic cells was determined by
epifluorescence microscopy 24 h after adding either 20
or 2  g/ml anti-CD3 antibody. Anti-IgG antibody was
added 30 min after anti-CD3 antibody. Error bars repre-
sent mean   SEM of multiple experiments. The asterisk
denotes the significant (P   0.01) inhibitory effect of Bcl-2
on apoptosis induction by 20  g/ml anti-CD3 antibody.
(D) Fluorescence microscopic images of Hoechst 33342–stained cells illustrating the typical apoptotic nuclear morphology induced by 20  g/ml anti-
CD3 antibody in Bcl-2–negative cells. Arrows denote cells having typical apoptotic nuclear morphology. Bars, 5  m.JCB • VOLUME 172 • NUMBER 1 • 2006 134
as reported previously by others, and is in contrast to the
more uniform pattern of Ca
2  oscillations observed in non-
lymphoid cells (for reviews see Lewis, 2001; Randriamampita
and Trautmann, 2004). The irregularity of anti-CD3–induced
Ca
2  oscillations necessitated a large number of experiments
to objectively compare oscillatory responses in Bcl-2–nega-
tive and –positive cells (Fig. 4). The only significant differ-
ences were an increase in oscillatory frequency (Fig. 4, A
and D) and duration of oscillations (Fig. 4 E) in Bcl-2–positive
cells. The oscillatory patterns induced in Bcl-2–negative and
–positive cells were indistinguishable in all other respects,
including the percentage of cells that developed oscillations
(Fig. 1 B), amplitude (Fig. 1 C), width of Ca
2  spikes (Fig. 1 D),
and latency period (Fig. 4 F). It has been reported that
NFAT is optimally activated by Ca
2  oscillations (Dol-
metsch et al., 1998; Tomida et al., 2003; for reviews see
Lewis, 2003; Winslow and Crabtree, 2005). Therefore,
NFAT activation was measured as a convenient “readout” of
the Ca
2  oscillations induced by anti-CD3 in WEHI7.2 cells.
Consistent with the finding that Bcl-2 did not inhibit anti-
CD3–induced Ca
2  oscillations, Bcl-2 did not inhibit NFAT
activation (Fig. 4 G).
The finding that Bcl-2 selectively inhibits the transient
Ca
2  elevation induced by high anti-CD3 without interfering
with Ca
2  oscillations induced by low anti-CD3 is relevant to
the role of Bcl-2 in regulating apoptosis, as WEHI7.2 cells un-
dergo apoptosis after treatment with high anti-CD3 but not
when treated with low anti-CD3 (Fig. 7 C). Moreover, apopto-
sis induction by high anti-CD3 was Ca
2  mediated (Fig. 7, A
and B), and the percentage of cells undergoing apoptosis was
proportional to the level of Ca
2  elevation (Fig. 6). These find-
ings are consistent with evidence that apoptosis induction after
TCR activation is triggered by InsP3 receptor–mediated Ca
2 
elevation (Nakayama et al., 1992; Jayaraman and Marks,
1997). Thus, by selectively repressing the Ca
2  elevation in-
duced by strong TCR activation, Bcl-2 inhibits apoptosis with-
out interfering with physiological Ca
2  signals induced by
weak TCR activation.
Figure 8. InsP3 receptor down-regulation
inhibits Ca
2  elevation induced by high but not
low anti-CD3. (A) Western blot showing levels
of InsP3Rs in WEHI7.2 cells treated with either
a nontargeting control siRNA pool (siNT) or
siRNA targeted toward all three InsP3R sub-
types (siInsP3R). The level of actin was mea-
sured as a loading control. Note that Westerns
for types 1 and 3 InsP3Rs were performed on
the same membrane, whereas the Western for
type 2 InsP3R was performed on a different
membrane. (B) Densitometric measurement of
InsP3R levels on Western blots, normalized to
actin, where the level of InsP3R after treatment
of cells with the siInsP3R is expressed as a per-
centage of the level after treatment with control
siNT. Error bars represent the mean   SEM of
three separate experiments. (C) Representative
Ca
2  traces indicating that knocking down
InsP3R levels inhibits the Ca
2  elevation in-
duced by 20  g/ml anti-CD3 antibody. Anti-
body was added during the first minute of the
trace. The data are from experiment 091905
and represent the mean   SEM of Ca
2  in 54
siNT-treated cells and 38 siInsP3R-treated cells.
(D) Mean Ca
2  elevation in siNT-treated cells
and siInsP3R-treated cells induced by 20  g/ml
anti-CD3 antibody. Data are from five experi-
ments in siNT-treated cells (349 cells total) and
five experiments in siInsP3R-treated cells (279
cells total). Error bars represent mean   SEM.
*, P   0.01. (E) Representative Ca
2  trace
from siNT-treated cells, where Ca
2  oscillations
were induced by 2  g/ml anti-CD3 antibody.
Antibody was added during the first 2 min of
the trace. (F) Representative Ca
2  trace from
siInsP3R-treated cells, where Ca
2  oscillations
were induced by 2  g/ml anti-CD3 antibody.
(G) The percentage of cells with no response to
2  g/ml anti-CD3 antibody or with develop-
ment of 1 or 2 or  3 spikes, comparing siNT-
and siInsP3R-treated cells. Error bars represent
mean   SEM. None of the differences were
significant (P   0.10). (H) The mean amplitude
of Ca
2  elevations induced by 2  g/ml anti-
CD3 antibody in siNT- and siInsP3R-treated
cells. Error bars represent mean   SEM. None
of the differences were significant (P   0.10).CALCIUM REGULATION BY BCL-2 • ZHONG ET AL. 135
The present findings are intriguing in light of the known
role of Bcl-2 in T cell development. T cells located in the thy-
mic cortex are TCR positive and both CD4  and CD8 
(“double positive”). At this stage of T cell development, Bcl-2
expression is low and cortical thymocytes are highly suscepti-
ble to apoptosis induction after TCR activation by antigen or
anti-CD3 antibody (Smith et al., 1989; Murphy et al., 1990; Shi
et al., 1991; Nakayama et al., 1992). When T cells mature and
migrate to the thymic medulla, they remain TCR positive but
become either CD4 CD8  or CD4 CD8  (“single positive”).
Bcl-2 expression is increased at this stage of development, and
as a consequence, single-positive thymocytes are less suscepti-
ble to apoptosis than are cortical thymocytes (Gratiot-Deans et
al., 1993; Veis et al., 1993). A strong correlation has been dem-
onstrated between Bcl-2 expression and susceptibility to Ca
2 -
induced apoptosis during T cell development (Andjelic et
al., 1993). Thymocytes at the earliest stage of development
(TCR CD4 CD8 ), the stage during which thymocytes re-
locate from bone marrow to thymus, express high levels of Bcl-2
and are resistant to Ca
2 -mediated apoptosis, whereas thy-
mocytes in the next stage of development (TCR CD4 CD8 )
are highly susceptible to Ca
2 -mediated apoptosis. It is in this
stage of development that thymocytes undergo either negative
or positive selection. Strong ligation of the TCR (e.g., by self-
peptide–major histocompatibility complex [MHC] complexes)
induces negative selection, whereas weak ligation of the TCR
(e.g., by foreign antigen–MHC complexes) induces positive se-
lection (for review see Hogquist, 2001; Neilson et al., 2004).
Double-positive thymocytes from Bcl-2–transgenic mice accu-
mulate excessively because of reduced negative selection and
are resistant to anti-CD3–induced apoptosis (for review see
Cory, 1995). Therefore, the role of Bcl-2 expression during T
cell development may be to regulate when and where negative
selection occurs. Decreased Bcl-2 expression in double-posi-
tive cortical thymocytes, but not in earlier or later stages of T cell
development, may limit negative selection to the cortical region
of the thymus and to this stage of development. Elevated Bcl-2
expression at earlier (double negative) and later (single positive)
stages of T cell development may dampen Ca
2  transients pro-
duced by strong TCR engagement while permitting repetitive
Ca
2  oscillations that signal cell proliferation and survival.
The mechanism by which Bcl-2 differentially regulates
Ca
2  elevation after strong but not weak TCR activation is not
entirely understood. In our earlier work (Chen et al., 2004), the
inhibitory effect of Bcl-2 on anti-CD3–induced Ca
2  elevation
appeared to be mediated at the level of the InsP3 receptor rather
than in upstream TCR signaling pathways. This conclusion was
based on two experimental strategies in which upstream TCR
signaling pathways were bypassed. In one strategy, we found
that Bcl-2 inhibited Ca
2  elevation induced by a cell-permeant
InsP3 ester. In the other strategy, we found that Bcl-2 inhibited
ER Ca
2  release induced by adding InsP3 to cells in which the
plasma membrane had been permeabilized by digitonin. In ad-
dition, Bcl-2 appeared to interact with InsP3 receptors, based on
results of blue native gel electrophoresis and coimmunoprecip-
itation (Chen et al., 2004). Finally, purified Bcl-2 inhibited
InsP3-gated single-channel opening when microsomal mem-
brane fractions containing InsP3 receptors were incorporated
into planar lipid bilayers (Chen et al., 2004). Therefore, the col-
lective evidence that Bcl-2 interacts with InsP3 receptors and
inhibits InsP3-mediated Ca
2  release from the ER raises the
question of whether the induction of Ca
2  oscillations by low
concentrations of anti-CD3 antibody is InsP3 receptor indepen-
dent or at least requires far fewer functional InsP3 receptors
than does the elevation of Ca
2  induced by a high concentra-
tion of anti-CD3 antibody.
To address this question, we used siRNA to reduce
InsP3 receptor levels in WEHI7.2 cells (Fig. 8). This proce-
dure inhibited Ca
2  elevation induced by strong TCR activa-
tion but did not inhibit the induction of Ca
2  oscillations by
weak TCR activation. In contrast, Ca
2  responses evoked in
HeLa cells by both high and low concentrations of ATP or
histamine were repressed by InsP3 receptor type 1 knockdown
(Hattori et al., 2004). Thus, mechanisms of Ca
2  oscillation
formation after TCR activation and G protein–coupled receptor
activation may differ. Our findings indicate that Ca
2  re-
sponses initiated by weak TCR activation are generated inde-
pendent of InsP3 receptor–mediated Ca
2  release or that only
a relatively small proportion of the full InsP3 receptor com-
plement is required to initiate Ca
2  signals in response to
weak TCR activation.
In future studies, the mechanism of how Bcl-2 regulates
InsP3 receptor function will be addressed in greater depth. In
preliminary studies, we found that Bcl-2 overexpression de-
creases InsP3 receptor phosphorylation in WEHI7.2 cells.
Moreover, it has recently been reported that Bcl-2 interacts
with InsP3 receptors in a manner that is dependent on the Bcl-2
phosphorylation state and may regulate Ca
2  dynamics in
the ER through regulation of InsP3 receptor phosphorylation
(Bassik et al., 2004; Oakes et al., 2005). Others have reported
that in neuronal cells Bcl-2 shuttles calcineurin to InsP3 recep-
tors and regulates Ca
2  release from internal stores (Erin et al.,
2003a,b; Erin and Billingsley, 2004). Therefore, one hypothe-
sis is that strong TCR signals enhance InsP3 receptor phosphor-
ylation, enhancing InsP3-induced Ca
2  release, and that Bcl-2
dampens the Ca
2  response to strong TCR activation by medi-
ating dephosphorylation of InsP3 receptors. Although untested,
this theory is consistent with evidence that phosphorylation
regulates the Ca
2  channel activity of InsP3 receptors (Cameron
et al., 1995; Jayaraman et al., 1996; deSouza et al., 2002;
Straub et al., 2002; Cui et al., 2004).
In summary, we previously discovered that the known
antiapoptotic protein Bcl-2 interacts with InsP3 receptors and
inhibits InsP3-induced Ca
2  release from the ER in T cells. In
this paper, we report that Bcl-2 selectively inhibits Ca
2  ele-
vation induced by high but not low anti-CD3. As a consequence,
Bcl-2 represses the transient elevation of Ca
2  associated with
apoptosis induction after strong TCR activation but does not
interfere with Ca
2  oscillations that activate NFAT after weak
TCR activation. The capacity of Bcl-2 to differentially regu-
late Ca
2  signals induced by strong versus weak TCR activa-
tion allows Bcl-2 to selectively inhibit apoptotic Ca
2  signals
without interfering with Ca
2  signals that mediate cell prolif-
eration and survival.JCB • VOLUME 172 • NUMBER 1 • 2006 136
Materials and methods
Reagents
EGTA and standard reagents were purchased from Sigma-Aldrich. Fura-
2–AM and Hoechst 33342 were purchased from Invitrogen. Hamster
anti–mouse CD3e   chain monoclonal antibody (clone 145-2C11) and
mouse anti–hamster IgG1 monoclonal antibody were obtained from BD
Biosciences. Mouse monoclonal antibody NFATc2 was obtained from
Santa Cruz Biotechnology, Inc.
Cell culture
WEHI7.2 cells were cultured in DME supplemented with 10% bovine calf
serum, 2 mM L-glutamine, and 100  M of nonessential amino acids.
Transfection procedures, isolation of Bcl-2–positive and –negative clones,
and the characterization of these clones were reported previously (Chen et
al., 2004).
Ca
2  imaging
Methods of Ca
2  imaging, described in detail previously (Chen et al.,
2004), were used here with only minor modifications. In brief, cells ad-
hered to poly-L-lysine–coated coverslips (35-mm coverslip dishes; MatTek
Corp.) were loaded with 1  M fura-2–AM for 45 min at 25 C in extracel-
lular buffer (ECB; 130 mM NaCl, 5 mM KCl, 1.5 mM CaCl2, 1 mM
MgCl2, 25 mM Hepes, pH 7.5, 1 mg/ml BSA, and 5 mM glucose). The
buffer was replaced with fresh ECB and the incubation was continued for
45 min at 25 C to permit deesterification. Culture dishes were mounted on
the nonheated stage of an inverted microscope (CKX41; Olympus)
equipped with a 20  fluor objective. Excitation light was alternated be-
tween 340 and 380 nm by a filter wheel (Sutter Instrument Co.), with 0.8-
and 0.2-s exposure times, respectively, and emitted light was filtered at
 510 nm and collected with an intensified charge-coupled device camera
(12-bit VGA; Cooke). Anti-CD3 antibody was gently added to buffer over-
laying the coverslip so as not to disturb cells loosely adherent to the cover-
slip. The video signal was digitized using InCyt Im2 software (Intracellular
Imaging) and subsequently processed using Excel (Microsoft). To deter-
mine Rmin, cells were perfused with ECB deficient in Ca
2  and supple-
mented with 4 mM EGTA and 10  M ionomycin. Rmax was obtained by
perfusing cells with ECB supplemented with 4 mM CaCl2 and 10  M ion-
omycin. Ca
2  concentration was calculated based on the published Kd for
fura-2 of 220 nM, by the equation of Grynkiewicz et al. (1985).
Fluorometric Ca
2  measurements
The measurement of Ca
2  concentration in cell suspensions by fluorometry
using fura-2–AM have been described in detail previously (Chen et al.,
2004).
NFAT Westerns
Cells were treated with 2  g/ml anti-CD3 antibody for various time peri-
ods at ambient temperature, after which they were placed on ice, pel-
leted, and resuspended in RIPA buffer (1% Triton X-100, 0.1% SDS, 50
mM Tris, pH 7.6, 150 mM NaCl, and 200 mM DTT) supplemented with
Complete mini protease inhibitors (Roche) and Phosphatase inhibitor cock-
tails I and II (Sigma-Aldrich). Cell extracts were resolved by electropho-
resis on 7% SDS–polyacrylamide gels under reducing conditions. The
separated proteins were transferred to Immobilon-P PVDF membranes (Mil-
lipore) and incubated with anti-NFATc2 antibody at a dilution of 1:500, fol-
lowed by incubation with horseradish peroxidase–conjugated goat anti–
mouse IgG and visualized by the ECL Western blotting detection reagent
(GE Healthcare).
InsP3 receptor Westerns
Western analysis for InsP3 receptors was performed as described previ-
ously (Chen et al., 2004). Protein samples were extracted as in the pre-
ceding method and resolved (60  g/lane) through 4–20% gradient gels
(Bio-Rad Laboratories). The antibodies for types 1 and 3 InsP3 receptors
were purchased from EMD Biosciences and BD Biosciences, respectively.
The antibody for type 2 InsP3 receptor was a gift from R. Wojcikiewicz
(State University of New York Upstate Medical University, Syracuse, NY).
The antibody for actin was obtained from Sigma-Aldrich. Secondary anti-
bodies were obtained from GE Healthcare.
Apoptosis assay
Cells were stained with Hoechst 33342 (final concentration 10  g/ml),
and typical apoptotic nuclear morphology was detected by epifluorescence
microscopy using a microscope (Axiovert S100; Carl Zeiss MicroImaging,
Inc.) equipped with a 63  oil/1.4 NA plan apochromat objective (Carl
Zeiss MicroImaging, Inc.) and a filter cube (model XF23; Omega Optical;
excitation   485 nm, emission   535 nm). Images were taken on a
charge-coupled device camera (ORCA C4742-95-cooled; Hamamatsu)
operating with Simple PCI software (Compix, Inc.).
Flow cytometry
Cells (1 million/ml) were loaded with 5  M calcium green–AM (Invitrogen)
for 45 min at 37 C in ECB. The cells were then pelleted and resuspended
in ECB at the same concentration and incubated at room temperature for
30 min to allow dye deesterification. The cells were then pelleted and con-
centrated to 5 million/ml. The cells were then analyzed and sorted on a
flow cytometer (Epics Elite; Beckman Coulter). Calcium green fluorescence
was measured after dye excitation with a 488-nM argon laser, and emit-
ted light collection was measured through a 525-nM band-pass filter. The
cells were initially run through the flow cytometer for 1 min to assess basal
cytosolic Ca
2 , and 20  g/ml anti-CD3 antibody was then added. The
cells were gated and sorted into two populations: cells with a high level of
Ca 
2  elevation and cells with a low level of Ca 
2  elevation. The sorted
cells were pelleted and resuspended in fresh culture medium and 20  g/ml
anti-CD3 antibody was re-added, and 30 min later an equal concentra-
tion of anti–hamster IgG was added. Apoptosis was measured 24 h later,
as described in the previous section.
RNA interference
The negative control, siCONTROL Non-Targeting siRNA Pool, and siGE-
NOME SMARTpools for all three subtypes of InsP3 receptor were pur-
chased from Dharmacon. After suspension in 1  siRNA buffer, SMART-
pools were added at a concentration of 1  M each to 0.2-cm cuvettes
containing 5 million WEHI7.2 cells suspended in 200  l Opti-MEM I (In-
vitrogen). Cuvettes were then subjected to a single 140V 10-ms
2–wave
pulse from a GenePulser Xcell (Bio-Rad Laboratories), and the contents of
the cuvette were immediately added to fresh media. Cells were grown in
culture after transfection for 48 h before use in experiments. Transfection
efficiency was measured by transfecting siGLO Cyclophilin (Dharmacon)
at a concentration of 1  M. After 30 min, cells were pelleted and then re-
suspended in phosphate-buffered saline. Cells were visualized by fluores-
cence microscopy, with excitation at 546 nm, and at least 200 cells were
counted in three separate experiments to determine the percentage of
transfected cells.
Statistical analysis
Comparisons were made using the two-tailed t test for two samples, assum-
ing equal variance.
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